Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma (Q34508586)

2 August 2017

Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma (English)

1 reference

2 August 2017

0 references

Nayak AS

1

1 reference

2 August 2017

Banov C

2

1 reference

2 August 2017

Corren J

3

1 reference

2 August 2017

Feinstein BK

4

1 reference

2 August 2017

Floreani A

5

1 reference

2 August 2017

Friedman BF

6

1 reference

2 August 2017

Goldsobel A

7

1 reference

2 August 2017

Gottschlich GM

8

1 reference

2 August 2017

Hannaway PJ

9

1 reference

2 August 2017

Lampl KL

10

1 reference

2 August 2017

Lapidus RJ

11

1 reference

2 August 2017

Lawrence M

12

1 reference

2 August 2017

Lumry W

13

1 reference

2 August 2017

Munk Z

14

1 reference

2 August 2017

Pearlman D

15

1 reference

2 August 2017

Scardella AT

16

1 reference

2 August 2017

Schenkel EJ

17

1 reference

2 August 2017

Segal AT

18

1 reference

2 August 2017

Segall N

19

1 reference

2 August 2017

Silverman B

20

1 reference

2 August 2017

Shneyer L

21

1 reference

2 August 2017

Nolop KB

22

1 reference

2 August 2017

Harrison JE

23

1 reference

2 August 2017

1 April 2000

1 reference

Annals of Allergy, Asthma & Immunology

2 August 2017

1 reference

2 August 2017

84

1 reference

2 August 2017

4

1 reference

2 August 2017

417-424

1 reference

Inhaled glucocorticoids for asthma

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

A comparison of the efficacy and safety of inhaled corticosteroids in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Nonadherence in asthmatic patients: is there a solution to the problem?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Measuring compliance with inhaled medication in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Cytokine inhibition by a novel steroid, mometasone furoate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Glucocorticosteroids inhibit leukotriene production

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

A scale for the measurement of quality of life in adults with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Efficacy and safety of inhaled corticosteroids. New developments

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Fluticasone propionate 50 micrograms BID versus 100 micrograms BID in the treatment of children with persistent asthma. Fluticasone Propionate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Effect of 1 year daily treatment with 400 microg budesonide (Pulmicort Turbuhaler) in newly diagnosed asthmatics.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

A multicenter, placebo-controlled study of twice daily triamcinolone acetonide (800 microg per day) for the treatment of patients with mild-to-moderate asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

A controlled trial of twice daily triamcinolone oral inhaler in patients with mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Once-daily budesonide in mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962275-2

7 January 2021

10.1016/S1081-1206(10)62275-2

Identifiers

DOI

1 reference

2 August 2017

1 reference